Killip Class Calculator

How to Use This Calculator

1. Select the Killip class that best matches the patient's clinical presentation.
2. In-hospital mortality (original and modern era) and management implications update instantly.
3. Use the Management by Class tab for detailed clinical guidance.
4. Use the Killip vs NYHA tab to understand the distinction between acute and chronic HF classification.

Formula

Example

Frequently Asked Questions

• What is the Killip classification? ▼
  The Killip classification is a four-category system for stratifying the severity of heart failure in patients with acute myocardial infarction, developed by Thomas Killip and John Kimball at New York Hospital and published in the American Journal of Cardiology in 1967. It was derived from an observation of 250 MI patients and remains the standard acute hemodynamic stratification tool in cardiology. Class I: No clinical signs of heart failure — no S3 gallop, no pulmonary rales, no elevated JVP. Class II: Mild heart failure — S3 gallop, rales in less than half of the lung fields, elevated JVP. Class III: Acute pulmonary edema — rales present in more than 50% of the lung fields, significant dyspnea and hypoxia. Class IV: Cardiogenic shock — systolic blood pressure below 90 mmHg with signs of end-organ hypoperfusion (cold and clammy extremities, altered mental status, oliguria, cyanosis). Original in-hospital mortality in the 1967 pre-thrombolytics/PCI era was: Class I 6%, Class II 17%, Class III 38%, Class IV 81%. Modern primary PCI has substantially reduced these numbers, but Killip class remains a powerful independent predictor of in-hospital and 30-day mortality.
• When is Killip used vs NYHA classification? ▼
  Killip and NYHA are often confused because both classify heart failure severity, but they are designed for entirely different clinical contexts and should never be conflated. Killip classification is specifically an acute MI tool — it is only applicable at the time of acute myocardial infarction hospitalization and describes the acuity of hemodynamic impairment at that single time point. It measures the acute consequence of ischemic injury on cardiac output and fluid balance. NYHA (New York Heart Association) functional classification, by contrast, is a tool for chronic heart failure — it describes a patient's functional capacity over weeks to months, categorizing symptoms from Class I (no limitation of physical activity) through Class IV (symptoms at rest). NYHA is dynamic and should be reassessed at every clinic visit for chronic HF patients: optimal guideline-directed medical therapy (beta-blockers, ACE inhibitors/ARBs, MRAs, SGLT2 inhibitors, sacubitril/valsartan) can improve a patient from NYHA Class III to Class II or even Class I. A patient who is Killip Class III at MI presentation may fully recover to NYHA Class I after successful PCI and optimal medical therapy.
• What is the mortality difference between Killip classes? ▼
  The mortality gradient across Killip classes is one of the steepest risk gradients in clinical cardiology. In the original 1967 Killip-Kimball derivation study (pre-thrombolytics, pre-PCI), in-hospital mortality was: Class I = 6%, Class II = 17%, Class III = 38%, Class IV = 81%. The extraordinary increase from Class I to Class IV represents a 13-fold difference in in-hospital mortality risk at baseline. In the contemporary primary PCI era, absolute mortality has fallen dramatically, but the gradient persists: Class I approximately 2-3%, Class II approximately 7-10%, Class III approximately 15-25%, Class IV approximately 40-60% even with aggressive management. Cardiogenic shock (Killip IV) remains the most feared complication of acute MI, accounting for approximately 7-10% of STEMI presentations and carrying mortality that has improved only modestly despite advanced therapies (primary PCI, vasopressors, intra-aortic balloon pump, Impella, ECMO). The SHOCK trial (Hochman et al. NEJM 1999) established that emergency revascularization significantly reduces 6-month mortality in cardiogenic shock, from approximately 50-60% to approximately 40-50% — still very high.
• How does Killip class change management? ▼
  Killip classification directly guides management intensity across multiple domains. Killip I patients receive standard post-MI care: aspirin, P2Y12 inhibitor, anticoagulation, beta-blocker, ACE inhibitor or ARB, high-intensity statin, and early revascularization (primary PCI for STEMI, or early invasive strategy for NSTEMI with high GRACE/TIMI). Killip II patients require supplemental oxygen, intravenous diuretics (furosemide) for fluid overload, nitrates if blood pressure permits, and may need step-down or CCU admission with continuous monitoring. ACE inhibitor or ARB is particularly important for secondary prevention when LV function is impaired. Killip III patients require ICU-level care with IV diuresis, non-invasive ventilation (CPAP or BiPAP) for respiratory failure, PA catheter consideration, and aggressive hemodynamic optimization before and after revascularization. Killip IV (cardiogenic shock) represents a medical emergency requiring vasopressor support (norepinephrine is first-line per current guidelines), inotropes (dobutamine for low output), mechanical circulatory support (IABP remains widely used; newer devices like Impella provide greater hemodynamic support), and emergent revascularization. Multi-organ failure is common in Killip IV, requiring intensive nephrology, respiratory, and hepatic support.
• Can a patient transition between Killip classes? ▼
  Yes, and transitions in either direction are clinically important. Deterioration from lower to higher Killip class — for example, from Class I to Class III or IV — can occur as a result of reinfarction, extension of the infarct territory, a mechanical complication (acute mitral regurgitation from papillary muscle rupture, ventricular septal defect, or free wall rupture), refractory arrhythmias, or suboptimal revascularization with ongoing ischemia. Development of cardiogenic shock several hours after initially stable presentation occurs in approximately 5% of STEMI patients and is associated with particularly poor prognosis because the diagnosis may be delayed. Improvement from a higher to a lower Killip class is also common and indicates effective treatment: successful primary PCI restoring coronary blood flow, effective diuresis reducing pulmonary congestion, vasopressor weaning, or mechanical circulatory support bridging to hemodynamic recovery. Serial reassessment of Killip class during hospitalization tracks clinical trajectory and guides escalation or de-escalation of monitoring and therapy. A patient initially Killip IV who stabilizes to Killip I or II with revascularization and MCS may be successfully bridged to mechanical support weaning or even transfer to a rehabilitation facility.

Related Calculators